Skip to main content

Laura Castillo Ribelles

Institutions of which they are part

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Laura Castillo Ribelles

Institutions of which they are part

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Projects

The Vall d’Hebron Iniciative for Parkinson associated to GBA (VHIP-GBA): from biospecimen collection to translational studies and therapies.

IP: Marta Martínez Vicente
Collaborators: José Antonio Arranz Amo, Jorge Hernández Vara, Eddie Pradas Gracia, Guillem Pintos Morell, Clara Carnicer Cáceres, Carles Lorenzo Bosquet, David Moreno Martinez, Daniela Samaniego Toro, Laura Castillo Ribelles, The Vall d’Hebron Iniciative for Parkinson associated to GBA (VHIP-GBA): from biospecimen collection to translational studies an
Funding agency: Instituto de Salud Carlos III
Funding: 245932.5
Reference: PI20/00728
Duration: 01/01/2021 - 30/06/2025

Demencia mixta por Alzheimer y enfermedad cerebrovascular: un estudio clínico y experimental.

IP: Maria Pilar Delgado Martínez
Collaborators: Francesc Pujadas Navinés, Olga Maisterra Santos, Laura Castillo Ribelles, Carles Lorenzo Bosquet, Antonio Palasi Franco, Maria Belén Gutiérrez Iglesias, Jesús Pizarro Gonzálvez, Diana Liebana Gutierrez
Funding agency: Instituto de Salud Carlos III
Funding: 134310
Reference: PI19/00217
Duration: 01/01/2020 - 30/06/2024

Desarrollo de una nueva terapia de reemplazo enzimático basada en nanotecnología para la enfermedad de Parkinson: restablecimiento de la actividad glucocerebrosidasa lisosomal mediante nanoconjugación enzima-polímero de GBA (NANO-ERT).

IP: Marta Martínez Vicente
Collaborators: Eddie Pradas Gracia, David Moreno Martinez, José Antonio Arranz Amo, Maria Camprodon Gomez, Laura Castillo Ribelles, Clara Carnicer Cáceres
Funding agency: Fundación Banco Bilbao Vizcaya Argentaria
Funding: 124047.74
Reference: BBVA/INVESTIGACIO/MARTINEZ
Duration: 01/05/2020 - 30/07/2023

Related news

The annual event offered a space for dialogue between the scientific community and society on how to address the future of ageing through research and innovation.

Docetaxel, carried by Soluplus, proved to be the most effective and least toxic combination to cross the blood-brain barrier and attack the tumour directly.

Based on the study led by VHIR, a clinical trial has been approved for patients with locally advanced pancreatic cancer.

Related professionals

Anna Jeanne Behr

Anna Jeanne Behr

Predoctoral researcher
Gene Therapy at Nervous System
Read more
Carme Garcia Esquerda

Carme Garcia Esquerda

Research technician
Basic, Translational and Clinical Pharmacy Research
Read more
Hanaa Boudoukhan Benriyyan

Hanaa Boudoukhan Benriyyan

Predoctoral researcher
Psychiatry, Mental Health and Addictions
Read more
Júlia Comulada Ferrer

Júlia Comulada Ferrer

Research technician
Clinical Neuroimmunology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.